再灌注治疗对肺栓塞患者血栓溶解及远期结局的影响
回顾性研究纳入382例肺栓塞患者,107例接受再灌注治疗。再灌注组诊断时血管阻塞指数更高(47% vs 28%)、右心劳损更多(81% vs 43%),但血管阻塞指数绝对下降更大(45% vs 26%)、右心室功能改善更明显(82% vs 65%)、12个月死亡率更低(2% vs 7%)且再入院率更低(33% vs 46%)。慢性血栓栓塞性肺动脉高压和肺栓塞复发无显著差异。
要点
- 接受再灌注治疗的患者基线血管阻塞指数和右心劳损比例更高
- 再灌注组血管阻塞指数绝对下降幅度更大(45% vs 26%;95%CI 14.0-25.6;P<.001)
- 再灌注组12个月死亡率(2% vs 7%)和再入院率(33% vs 46%)更低
核心结论
- 在肺栓塞患者中观察到再灌注治疗与更好的生存、更大幅度的血栓溶解和右心室功能改善相关。
研究设计与样本
- 回顾性研究,基于肺栓塞反应团队登记数据库,纳入在3至12个月间有重复影像检查的患者,共382例,其中107例接受再灌注治疗后抗凝治疗。
主要发现
- 再灌注组诊断时血管阻塞指数为47% vs 未再灌注组28%(P<.001),超声心动图右心劳损征象为81% vs 43%(P<.001)。
- 血管阻塞指数绝对下降为45% vs 26%(95%CI 14.0-25.6;P<.001),右心室功能改善为82% vs 65%(P=.021)。
- 12个月死亡率为2% vs 7%(P=.038),再入院率为33% vs 46%(P=.031)。
- 慢性血栓栓塞性肺动脉高压发生率为8% vs 5%(P=.488),肺栓塞复发率为8% vs 6%(P=.646),均无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Major progress in reperfusion strategies has substantially improved the short-term outcomes of patients with pulmonary embolism (PE), however, up to 50% of patients report persistent dyspnea after acute PE. METHODS: A retrospective study of the PE response team registry and included patients with repeat imaging at 3 to 12 months. The primary outcome was to determine the incidence of residual pulmonary vascular obstruction following acute PE. Secondary outcomes included the development of PE recurrence, right ventricular (RV) dysfunction, chronic thromboembolic pulmonary hypertension, readmission, and mortality at 12 months. RESULTS: A total of 382 patients were included, and 107 patients received reperfusion therapies followed by anticoagulation. Patients who received reperfusion therapies including systemic thrombolysis, catheter-directed thrombolysis, and mechanical thrombectomy presented with a higher vascular obstructive index (47% vs 28%; P < .001) and signs of right heart strain on echocardiogram (81% vs 43%; P < .001) at the time of diagnosis. A higher absolute reduction in vascular obstructive index (45% vs 26%; 95% confidence interval, 14.0-25.6; P < .001), greater improvement in RV function (82% vs 65%; P = .021), and lower 12-month mortality rate (2% vs 7%; P = .038) and readmission rate (33% vs 46%; P = .031) were observed in the reperfusion group. No statistically significant differences were found between groups in the development of chronic thromboembolic pulmonary hypertension (8% vs 5%; P = .488) and PE recurrence (8% vs 6%; P = .646). CONCLUSIONS: We observed a favorable survival and greater improvement in clot resolution and RV function in patients treated with reperfusion therapies.
引用
- Lio KU, Bashir R, Lakhter V, et al. Impact of reperfusion therapies on clot resolution and long-term outcomes in patients with pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38369293. doi:10.1016/j.jvsv.2024.101823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。